Blog

11 May, 2022

How Liquid Biopsy Technology is Changing What’s Possible in Cancer Treatment

Erin Newburn, MS, PhD Sr. Director, Field Applications Scientist How Liquid Biopsy Technology is Changing What's Possible in Cancer Treatment There’s no doubt that early detection is essential for good outcomes when dealing with cancer treatment, and this is equally true when detecting disease recurrence. Patients who have already undergone [...]

4 May, 2022

Understanding and Evaluating the Latest Advances in Liquid Biopsy Technology

Dan Norton Associate Director, Product Management Personalis, Inc. Understanding and Evaluating the Latest Advances in Liquid Biopsy Technology Liquid biopsies are a hot topic in oncology, and for good reason. Some tout them as a relatively painless alternative to operations that can be difficult, expensive, and extremely uncomfortable. While others [...]

29 Apr, 2022

Whole-genome sequencing approach for cancer validated by Cambridge study

Dan Norton Associate Director, Product Management Personalis, Inc. Whole-genome sequencing approach for cancer validated by Cambridge study One of the most interesting aspects of precision medicine is that in order to treat each person’s disease individually, we have to understand how the disease looks across a population. In other words, [...]

7 Oct, 2021

Prevailing Cancer Immunotherapy Challenges

Kedar Hastak, MS, PhD Manager, Field Applications Scientist Prevailing Cancer Immunotherapy Challenges In recent years, we have made great strides in our understanding of the complex interaction between the immune system and cancer which have led to significant advances in cancer immunotherapies (CI). Despite the successful application of CI [...]

29 Jun, 2021

Leveraging RNA Sequencing Data in Predicting Immunotherapy Response

Erin Newburn, MS, PhD Sr. Director, Field Application Scientist Leveraging RNA Sequencing Data in Predicting Immunotherapy Response Can transcriptomics help us fine tune tumor specific responses and transform personalization of therapy? The complexity of understanding immune checkpoint blockade response has been abundantly documented in recent studies. Also increasingly studied is [...]

24 Feb, 2021

Neoantigen-based Cancer Therapies

Christelle Johnson, MS, PhD Senior Field Applications Scientist Cancer Genomics & Immuno-Oncology Neoantigen-based cancer immunotherapies We are witnessing one of the most accelerated scientific efforts in response to the COVID-19 pandemic.  Among these efforts that include sequencing the virus, designing the very first prophylactic vaccines, conducting clinical trials, demonstrating efficacy, [...]

7 Jan, 2021

Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy

Dan Brudzewsky, PhD Senior Field Applications Scientist - UK & Nordics Travis Yates, PhD Field Applications Scientist Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy Within recent years, the field of oncology has seen major advancements in regards to therapeutic options for patients. Immunotherapy, which relies on [...]

Go to Top